A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain
Latest Information Update: 08 Jun 2023
At a glance
- Drugs ETX 018810 (Primary)
- Indications Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Eliem Therapeutics
- 02 Aug 2022 According to an Eliem Therapeutics media release, based on results from this trial and NCT04688671 trial the company has decided to discontinue development of ETX-810.
- 02 Aug 2022 Primary endpoint has not been met. (Change from baseline to Week 4 in the weekly average of the daily pain score), according to an Eliem Therapeutics media release.
- 02 Aug 2022 Results presented in the Eliem Therapeutics Media Release.